Gene signature-based prediction of triple-negative breast cancer patient response to Neoadjuvant chemotherapy.

ABSTRACT: Neoadjuvant chemotherapy is the current standard of care for large, advanced, and/or inoperable tumors, including triple-negative breast cancer. Although the clinical benefits of neoadjuvant chemotherapy have been illustrated through numerous clinical trials, more than half of the patients do not experience therapeutic benefit and needlessly suffer from side effects. Currently, no clinically applicable biomarkers are available for predicting neoadjuvant chemotherapy response in triple-negative breast cancer; the discovery of such a predictive biomarker or marker profile is an unmet need. In this study, we introduce a generic computational framework to calculate a response-probability score (RPS), based on patient transcriptomic profiles, to predict their response to neoadjuvant chemotherap

SUBMITTER: Zhao Y 

PROVIDER: S-EPMC7476842 | biostudies-literature | 2020 Sep

REPOSITORIES: biostudies-literature